
Sign up to save your podcasts
Or


In this episode of Unscripted, the AMCP podcast, host Laura Bobolts, PharmD, BCOP, talks with Kirollos Hanna, PharmD, Director of Pharmacy at Minnesota Oncology, about the rapidly shifting treatment landscape for chronic lymphocytic leukemia (CLL). The discussion covers the transition toward oral fixed-duration frontline regimens, the latest 2026 NCCN guidelines, and the emerging role of MRD testing. They also explore the clinical and economic implications of these therapies, including how the Inflation Reduction Act (IRA) is reshaping Medicare formulary strategies and patient access.
By AMCPIn this episode of Unscripted, the AMCP podcast, host Laura Bobolts, PharmD, BCOP, talks with Kirollos Hanna, PharmD, Director of Pharmacy at Minnesota Oncology, about the rapidly shifting treatment landscape for chronic lymphocytic leukemia (CLL). The discussion covers the transition toward oral fixed-duration frontline regimens, the latest 2026 NCCN guidelines, and the emerging role of MRD testing. They also explore the clinical and economic implications of these therapies, including how the Inflation Reduction Act (IRA) is reshaping Medicare formulary strategies and patient access.